Miller Brendan J, Murray Linda, Beckmann Michael M, Kent Terrence, Macfarlane Bonnie
Department of Obstetrics and Gynaecology, Flinders Medical Centre, Flinders Drive, Bedford Park, South Australia, Australia, 5042.
Cochrane Database Syst Rev. 2013 Oct 24;2013(10):CD009104. doi: 10.1002/14651858.CD009104.pub2.
Postnatal depression is a medical condition that affects many women and the development of their infants. There is a lack of evidence for treatment and prevention strategies that are safe for mothers and infants. Certain dietary deficiencies in a pregnant or postnatal woman's diet may cause postnatal depression. By correcting these deficiencies postnatal depression could be prevented in some women. Specific examples of dietary supplements aimed at preventing postnatal depression include: omega-3 fatty acids, iron, folate, s-adenosyl-L-methionine, cobalamin, pyridoxine, riboflavin, vitamin D and calcium.
To assess the benefits of dietary supplements for preventing postnatal depression either in the antenatal period, postnatal period, or both.
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013).
Randomised controlled trials, involving women who were pregnant or who had given birth in the previous six weeks, who were not depressed or taking antidepressants at the commencement of the trials. The trials could use as intervention any dietary supplementation alone or in combination with another treatment compared with any other preventive treatment, or placebo, or standard clinical care.
Two review authors independently assessed trials for inclusion and assessed the risk of bias for the two included studies. Two review authors extracted data and the data were checked for accuracy.
We included two randomised controlled trials.One trial compared oral 100 microgram (µg) selenium yeast tablets with placebo, taken from the first trimester until birth. The trial randomised 179 women but outcome data were only provided for 85 women. Eighty-three women were randomised to each arm of the trial. Sixty-one women completed the selenium arm, 44 of whom completed an Edinburgh Postnatal Depression Scale (EPDS). In the placebo arm, 64 women completed the trial, 41 of whom completed an EPDS. This included study (n = 85) found selenium had an effect on EPDS scores but did not reach statistical significance (P = 0.07). There was a mean difference (MD) of -1.90 (95% confidence interval (CI) -3.92 to 0.12) of the self-reported EPDS completed by participants within eight weeks of delivery. There was a high risk of attrition bias due to a large proportion of women withdrawing from the study or not completing an EPDS. This included study did not report on any of the secondary outcomes of this review.The other trial compared docosahexanoic acid (DHA) and eicosapentaenoic acid (EPA) with placebo. The trial randomised 126 women at risk of postpartum depression to three arms: 42 were allocated to EPA, 42 to DHA, and 42 to placebo. Three women in the EPA arm, four in the DHA arm, and one woman in the placebo arm were lost to follow-up. Women who were found to have major depressive disorder, bipolar disorder, current substance abuse or dependence, suicidal ideation or schizophrenia at recruitment were excluded from the study. The women who discontinued the intervention (five in the EPA arm, four in the DHA arm and seven in the placebo arm) were included in the intention-to-treat analysis, while those who were lost to follow-up were not. Women received supplements or placebo from recruitment at a gestational age of 12 to 20 weeks until their final review visit six to eight weeks postpartum. The primary outcome measure was the Beck Depression Inventory (BDI) score at the fifth visit (six to eight weeks postpartum). No benefit was found for EPA-rich fish oil (MD 0.70, 95% CI -1.78 to 3.18) or DHA-rich fish oil supplementation (MD 0.90, 95% CI -1.33 to 3.13) in preventing postpartum depression. No difference was found in the effect on postnatal depression comparing EPA with DHA (MD -0.20, 95% CI -2.61 to 2.21). No benefit or significant effect was found in terms of the secondary outcomes of the presence of major depressive disorder at six to eight weeks postpartum, the number of women who commenced antidepressants, maternal estimated blood loss at delivery or admission of neonates to the neonatal intensive care unit.
AUTHORS' CONCLUSIONS: There is insufficient evidence to conclude that selenium, DHA or EPA prevent postnatal depression. There is currently no evidence to recommend any other dietary supplement for prevention of postnatal depression.
产后抑郁症是一种影响许多女性及其婴儿发育的病症。对于对母亲和婴儿安全的治疗和预防策略,缺乏证据支持。孕妇或产后女性饮食中的某些营养缺乏可能导致产后抑郁症。通过纠正这些缺乏,在一些女性中可以预防产后抑郁症。旨在预防产后抑郁症的膳食补充剂的具体例子包括:ω-3脂肪酸、铁、叶酸、S-腺苷-L-甲硫氨酸、钴胺素、吡哆醇、核黄素、维生素D和钙。
评估膳食补充剂在孕期、产后或两者期间预防产后抑郁症的益处。
我们检索了Cochrane妊娠和分娩组试验注册库(2013年4月30日)。
随机对照试验,涉及怀孕或在过去六周内分娩的女性,她们在试验开始时未患抑郁症或未服用抗抑郁药。试验可以将任何单独的膳食补充剂或与另一种治疗联合使用作为干预措施,与任何其他预防性治疗、安慰剂或标准临床护理进行比较。
两位综述作者独立评估试验是否纳入,并评估两项纳入研究的偏倚风险。两位综述作者提取数据,并对数据的准确性进行检查。
我们纳入了两项随机对照试验。一项试验比较了从孕早期至分娩服用口服100微克硒酵母片与安慰剂的效果。该试验将179名女性随机分组,但仅为85名女性提供了结局数据。试验的每个组随机分配了83名女性。硒组有61名女性完成试验,其中44名完成了爱丁堡产后抑郁量表(EPDS)。在安慰剂组,64名女性完成试验,其中41名完成了EPDS。这项纳入研究发现硒对EPDS评分有影响,但未达到统计学显著性(P = 0.07)。在分娩后八周内,参与者自我报告的EPDS的平均差异(MD)为-1.90(95%置信区间(CI)-3.92至0.12)。由于很大一部分女性退出研究或未完成EPDS,存在较高的失访偏倚风险。这项纳入研究未报告本综述的任何次要结局。另一项试验比较了二十二碳六烯酸(DHA)和二十碳五烯酸(EPA)与安慰剂的效果。该试验将126名有产后抑郁症风险的女性随机分为三组:42名分配到EPA组,42名分配到DHA组,42名分配到安慰剂组。EPA组有3名女性、DHA组有4名女性和安慰剂组有1名女性失访。在招募时被发现患有重度抑郁症、双相情感障碍、当前药物滥用或依赖、自杀意念或精神分裂症的女性被排除在研究之外。中断干预的女性(EPA组5名、DHA组4名和安慰剂组7名)被纳入意向性分析,而失访的女性未纳入。女性从孕12至20周招募时开始接受补充剂或安慰剂,直至产后六至八周的最后一次复查。主要结局指标是第五次访视(产后六至八周)时的贝克抑郁量表(BDI)评分。未发现富含EPA的鱼油(MD 0.70,95% CI -1.78至3.18)或富含DHA的鱼油补充剂在预防产后抑郁症方面有益处。比较EPA与DHA对产后抑郁症的影响未发现差异(MD -0.20,95% CI -2.61至2.21)。在产后六至八周患重度抑郁症的次要结局、开始服用抗抑郁药的女性人数、分娩时产妇估计失血量或新生儿入住新生儿重症监护病房方面,未发现益处或显著效果。
没有足够的证据得出硒、DHA或EPA可预防产后抑郁症的结论。目前没有证据推荐任何其他膳食补充剂用于预防产后抑郁症。